WuXi Biologics Announces $450 Million Bispecific Deal with Oxford BioTherapeutics

WuXi Biologics formed a $450 million partnership with England's Oxford BioTherapeutics to develop five novel bispecific antibodies, including a PD-L1 molecule, using its WuXiBody™ Platform. OBT says the bispecifics will combine two second-gen immunoncology targeting mechanisms in a single molecule to improve efficacy. Oxford will make an upfront payment plus milestones and royalties, though details were not disclosed. More details...

Stock Symbol: (HK: 2269)

Share this with colleagues:

More From BioPortfolio on "WuXi Biologics Announces $450 Million Bispecific Deal with Oxford BioTherapeutics"